Pyxis Oncology (NASDAQ: PYXS) — Perfil da empresa, notícias e dados financeiros
Pyxis Oncology is a biotechnology firm advancing novel cancer therapies with a pipeline focused on antibody-drug conjugates and immunotherapies.
Pyxis Oncology
Pyxis Oncology (NASDAQ:PYXS) is a biotechnology firm focused on developing novel therapies for cancer and other hard-to-treat diseases. The company's operations revolve around advancing a diverse pipeline of antibody-drug conjugates (ADCs) and immuno-oncology therapies designed to address the limitations of current treatments. With an emphasis on innovation and collaboration, Pyxis Oncology engages in rigorous research and development projects, aiming to bring breakthrough therapies to patients in need. The firm's objectives center on achieving clinical milestones, fostering partnerships with leading research institutions, and ultimately improving patient outcomes across various cancer indications. Through its dedicated efforts, Pyxis Oncology strives to redefine cancer treatment paradigms and deliver hope to those affected by malignancies.
Resumo
Operações
Produtos e/ou serviços de Pyxis Oncology
- Developing novel antibody-drug conjugates for targeting solid tumors and improving outcomes in cancer patients.
- Creating innovative bi-specific antibodies designed to engage the immune system against cancer.
- Advancing a pipeline of immune-oncology therapies aimed at enhancing the body's ability to fight cancer.
- Development of targeted therapies for difficult-to-treat cancers using a precision medicine approach.
- Research on leveraging unique antibody platforms to disrupt cancer cell signaling and inhibit tumor growth.
- Exploration of strategic partnerships and collaborations to accelerate the development of promising cancer treatments.
equipe executiva do Pyxis Oncology
- Thomas CivikCEO & Chairman
- Jitendra WadhaneChief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer
- Balu N. BalasubramanianInterim Chief Technology Officer
- Donna RegaladoHead of Human Resources
- Charles T. GombarSenior Vice President of Portfolio & Program Management
- Michael BuiSenior Vice President of Global Regulatory Affairs
- Supriya RothHead of Commercial Development
- Shui HeHead of Biometrics
- Hongwei WangHead of ADC Development & Clinical Strategy
- Marsha CrochiereHead of Translational Medicine & Research
Últimas notícias sobre a Pyxis Oncology
Principais indicadores financeiros
Resultados divulgados pela Pyxis Oncology, em USD.
- Cap. de mercado
- 219,8 mi
- Receita (TTM)
- 11 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 13,9 mi | -84,4 mi | -79,6 mi | |
| 16,1 mi | -89,5 mi | -77,3 mi | |
| 0 | -82,2 mi | -73,8 mi | |
| 0 | -123,5 mi | -118 mi |